Loading...
Clinical Prognostic Factors in Patients With Metastatic Adrenocortical Carcinoma Treated With Second Line Gemcitabine Plus Capecitabine Chemotherapy
Gemcitabine plus Capecitabine (Gem/Cape) is a frequently adopted second line chemotherapy for metastatic adrenocortical carcinoma (ACC), but only a minority of patients is destined to obtain a clinical benefit. The identification of baseline predictive factors of efficacy is relevant. We retrospecti...
Na minha lista:
| Udgivet i: | Front Endocrinol (Lausanne) |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Frontiers Media S.A.
2021
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7943871/ https://ncbi.nlm.nih.gov/pubmed/33716976 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fendo.2021.624102 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|